{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:45:35Z","timestamp":1792784735690,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00292-026-01575-6","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:41:07Z","timestamp":1781793667000},"page":"472-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie des Melanoms","Therapy of melanoma"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1165-3979","authenticated-orcid":false,"given":"Isabel","family":"Hariri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"1","key":"1575_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka\u00a0RHI, Collichio\u00a0F, Harrington\u00a0KJ et\u00a0al (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J\u00a0Immunother Cancer 7(1):145. https:\/\/doi.org\/10.1186\/s40425-019-0623-z","journal-title":"J Immunother Cancer"},{"key":"1575_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","volume":"126","author":"PA Ascierto","year":"2020","unstructured":"Ascierto\u00a0PA, Dummer\u00a0R, Gogas\u00a0HJ et\u00a0al (2020) Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer 126:33\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.016","journal-title":"Eur J Cancer"},{"issue":"2","key":"1575_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto\u00a0PA, Mandal\u00e0\u00a0M, Ferrucci\u00a0PF et\u00a0al (2023) Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. J\u00a0Clin Oncol 41(2):212\u2013221. https:\/\/doi.org\/10.1200\/JCO.21.02961","journal-title":"J Clin Oncol"},{"key":"1575_CR4","unstructured":"AWMF Leitlinie 032\/041 \u2013 Diagnostik, Therapie und Nachsorge des malignen Melanoms (2022) Version 2.2. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/032-041.html. Zugegriffen: 13. Jan. 2026"},{"issue":"10","key":"1575_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner\u00a0A, Corrie\u00a0PG, Hamid\u00a0O (2023) Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clin Cancer Res 29(10):1835\u20131854. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1922","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1575_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank\u00a0CU, Lucas\u00a0MW, Scolyer\u00a0RA et\u00a0al (2024) Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 391(18):1696\u20131708. https:\/\/doi.org\/10.1056\/NEJMoa2402604","journal-title":"N Engl J Med"},{"issue":"6892","key":"1575_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies\u00a0H, Bignell\u00a0GR, Cox\u00a0C et\u00a0al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"1575_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327","volume":"211","author":"AM Eggermont","year":"2024","unstructured":"Eggermont\u00a0AM, Kicinski\u00a0M, Blank\u00a0CU et\u00a0al (2024) Seven-year analysis of adjuvant pembrolizumab versus placebo in stage\u00a0III melanoma in the EORTC1325 \/ KEYNOTE-054 trial. Eur J Cancer 211:114327. https:\/\/doi.org\/10.1016\/j.ejca.2024.114327","journal-title":"Eur J Cancer"},{"issue":"23","key":"1575_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries\u00a0MB, Thompson\u00a0JF, Cochran\u00a0AJ et\u00a0al (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376(23):2211\u20132222. https:\/\/doi.org\/10.1056\/NEJMoa1613210","journal-title":"N Engl J Med"},{"issue":"3","key":"1575_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling\u00a0L, Eigentler\u00a0TK, Fluck\u00a0M et\u00a0al (2019) Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4(3):e000491. https:\/\/doi.org\/10.1136\/esmoopen-2019-000491","journal-title":"ESMO Open"},{"key":"1575_CR11","unstructured":"https:\/\/www.klinikum.uni-heidelberg.de\/en\/hautklinik-zentrum\/hauttumorzentrum\/forschung\/datenbank-seltene-braf-mutationen\/ Zugegriffen: 22. Jan. 2026"},{"issue":"6","key":"1575_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/CMR.0000000000000832","volume":"32","author":"RK Ismail","year":"2022","unstructured":"Ismail\u00a0RK, Suijkerbuijk\u00a0KPM, de Boer\u00a0A et\u00a0al (2022) Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Res 32(6):460\u2013468. https:\/\/doi.org\/10.1097\/CMR.0000000000000832","journal-title":"Melanoma Res"},{"issue":"10","key":"1575_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.annonc.2025.06.014","volume":"36","author":"KC K\u00e4hler","year":"2025","unstructured":"K\u00e4hler\u00a0KC, Hassel\u00a0JC, Ziemer\u00a0M et\u00a0al (2025) Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma. Ann Oncol 36(10):1166\u20131177. https:\/\/doi.org\/10.1016\/j.annonc.2025.06.014","journal-title":"Ann Oncol"},{"key":"1575_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115124","volume":"216","author":"L Kandolf","year":"2025","unstructured":"Kandolf\u00a0L, Ascierto\u00a0PA, Bastholt\u00a0L et\u00a0al (2025) An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology. Eur J Cancer 216:115124. https:\/\/doi.org\/10.1016\/j.ejca.2024.115124","journal-title":"Eur J Cancer"},{"issue":"17","key":"1575_CR15","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin\u00a0J, Del Vecchio\u00a0M, Mandal\u00e1\u00a0M et\u00a0al (2023) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5\u2011Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res 29(17):3352\u20133361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3145","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1575_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long\u00a0GV, Carlino\u00a0MS, McNeil\u00a0C et\u00a0al (2024) Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol 35(12):1191\u20131199. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2330","journal-title":"Ann Oncol"},{"issue":"18","key":"1575_CR17","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","volume":"391","author":"GV Long","year":"2024","unstructured":"Long\u00a0GV, Hauschild\u00a0A, Santinami\u00a0M et\u00a0al (2024) Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 391(18):1709\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2404139","journal-title":"N Engl J Med"},{"issue":"9","key":"1575_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel\u00a0SP, Othus\u00a0M, Chen\u00a0Y et\u00a0al (2023) Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 388(9):813\u2013823. https:\/\/doi.org\/10.1056\/NEJMoa2211437","journal-title":"N Engl J Med"},{"issue":"8","key":"1575_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16081046","volume":"16","author":"R Reschke","year":"2024","unstructured":"Reschke\u00a0R, Enk\u00a0AH, Hassel\u00a0JC (2024) T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma. Pharmaceutics 16(8):1046. https:\/\/doi.org\/10.3390\/pharmaceutics16081046","journal-title":"Pharmaceutics"},{"issue":"1","key":"1575_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae008","volume":"4","author":"AR Ribeiro","year":"2024","unstructured":"Ribeiro\u00a0AR, Britton-Rivet\u00a0C, Collins\u00a0L et\u00a0al (2024) High-affinity T cell receptor ImmTAC\u00ae bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME. Immunother Adv 4(1):ltae008. https:\/\/doi.org\/10.1093\/immadv\/ltae008","journal-title":"Immunother Adv"},{"issue":"10151","key":"1575_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf\u00a0D, van Akkooi\u00a0ACJ, Berking\u00a0C et\u00a0al (2018) Melanoma. Lancet 392(10151):971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(18)31559-9","journal-title":"Lancet"},{"issue":"36","key":"1575_CR22","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider\u00a0BJ, Naidoo\u00a0J, Santomasso\u00a0BD et\u00a0al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J\u00a0Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"1","key":"1575_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Wagle\u00a0NS, Jemal\u00a0A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1575_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells15020099","volume":"15","author":"CK Sisk","year":"2026","unstructured":"Sisk\u00a0CK, Turner\u00a0LM, Meraj\u00a0S et\u00a0al (2026) Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms. Cells 15(2):99. https:\/\/doi.org\/10.3390\/cells15020099","journal-title":"Cells"},{"key":"1575_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb\u00a0T, Wessely\u00a0A, Petzold\u00a0A et\u00a0al (2021) c\u2011Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer 157:348\u2013357. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.015","journal-title":"Eur J Cancer"},{"issue":"1","key":"1575_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi\u00a0HA, Schadendorf\u00a0D, Lipson\u00a0EJ et\u00a0al (2022) Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"issue":"10427","key":"1575_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber\u00a0JS, Carlino\u00a0MS, Khattak\u00a0A et\u00a0al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403(10427):632\u2013644. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7","journal-title":"Lancet"},{"issue":"7","key":"1575_CR28","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke\u00a0M, Araujo\u00a0DM, Chatterjee\u00a0M et\u00a0al (2025) Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med 31(7):2365\u20132374. https:\/\/doi.org\/10.1038\/s41591-025-03650-6","journal-title":"Nat Med"},{"issue":"1","key":"1575_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok\u00a0JD, Chiarion-Sileni\u00a0V, Rutkowski\u00a0P et\u00a0al (2025) Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417","journal-title":"N Engl J Med"},{"issue":"12","key":"1575_CR30","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1002\/cam4.2248","volume":"8","author":"Q Yu","year":"2019","unstructured":"Yu\u00a0Q, Xie\u00a0J, Li\u00a0J, Lu\u00a0Y, Liao\u00a0L (2019) Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review. Cancer Med 8(12):5414\u20135424. https:\/\/doi.org\/10.1002\/cam4.2248","journal-title":"Cancer Med"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01575-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01575-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01575-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:02:05Z","timestamp":1792782125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01575-6"}},"subtitle":["Aktuelle Standards und Perspektiven","Current standards and future perspectives"],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01575-6","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Hariri gibt an, dass kein Interessenkonflikt besteht. J.C.\u00a0Hassel erhielt Referentenhonorare von Amgen, BMS, Delcath, Immunocore, MSD, Novartis, Pierre Fabre, Replimune, Regeneron und Sunpharma sowie Honorare f\u00fcr die Teilnahme an Advisory Boards von Delcath und Sunpharma.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}